What's in Suzhou Zelgen Biopharmaceuticals Co.,Ltd's pipeline?

Suzhou Zelgen Biopharmaceuticals Co.,Ltd has 18 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 2 in Phase 2, 10 in Phase 1.

Which companies overlap with Suzhou Zelgen Biopharmaceuticals Co.,Ltd's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, University College, London, National Institute of Allergy and Infectious Diseases (NIAID), ATGC Co., Ltd., Akeso.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/suzhou-zelgen-biopharmaceuticals-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Suzhou Zelgen Biopharmaceuticals Co.,Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Suzhou Zelgen Biopharmaceuticals Co.,Ltd pipeline: 1 marketed, 0 filed, 5 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 2 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Rifampicin Capsules	Rifampicin Capsules	marketed	Rifamycin antibiotic	Bacterial RNA polymerase	Infectious Disease
Jaktinib	Jaktinib	phase 3			Other
Hydroxycarbamide Tablets	Hydroxycarbamide Tablets	phase 3	Ribonucleotide reductase inhibitor	Ribonucleotide reductase	Oncology; Hematology
Placebo to match Hydroxycarbamide	Placebo to match Hydroxycarbamide	phase 3
Placebo to match Jaktinib	Placebo to match Jaktinib	phase 3
ZG006	ZG006	phase 3	PD-1 inhibitor	PD-1	Oncology

Therapeutic area mix

Other · 2
Infectious Disease · 1
Oncology · 1
Oncology; Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
University College, London · 2 shared drug classes
National Institute of Allergy and Infectious Diseases (NIAID) · 2 shared drug classes
ATGC Co., Ltd. · 1 shared drug class
Akeso · 1 shared drug class
Amgen · 1 shared drug class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Asahi Kasei Pharma Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Suzhou Zelgen Biopharmaceuticals Co.,Ltd:

Cite this brief

Drug Landscape (2026). Suzhou Zelgen Biopharmaceuticals Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzhou-zelgen-biopharmaceuticals-co-ltd. Accessed 2026-05-16.